Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 8/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7931609 | 0.84 | CYP2C19 (0.33) | KDM4EMAPTLMNAALDH1A1MEN1 | |
| SCHEMBL43927 | 0.80 | KDM4E (0.40) | KDM4EMAPTSTAT3CTDSP1SIRT5 | |
| SCHEMBL5495749 | 0.79 | — | — | |
| SCHEMBL4432960 | 0.79 | PTPN1 (0.38) | KDM4EMAPTLMNAALDH1A1MEN1 | |
| SCHEMBL5137956 | 0.71 | ALDH1A1 (0.36) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2179698 | 0.70 | ALDH1A1 (0.40) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL10105974 | 0.69 | L3MBTL1 (0.42) | KDM4EMAPTLMNAALDH1A1MEN1 | |
| SCHEMBL7769435 | 0.68 | ALDH1A1 (0.41) | KDM4EMAPTSTAT3CTDSP1SIRT5 | |
| SCHEMBL30358600 | 0.66 | ALDH1A1 (0.39) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5576207 | 0.66 | PKM (0.40) | KDM4EMAPTLMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151999-A1 | POLYMERIZED HEMOGLOBIN SIZE FRACTIONATED VIA TANGENTIAL FLOW FILTRATION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-18 | — | — | WO | claimed |
| US-11712423-B2 | Methods and compositions for modifying mucous membranes | ABBOTT NICHOLAS L (US) | 2023-08-01 | — | — | US | claimed |
| US-11576896-B2 | Benzoselenophene-based compounds, pharmaceutical compositions and antibody-drug conjugates including the same | AIMED BIO INC. (KR) | 2023-02-14 | — | — | US | claimed |
| EP-4103585-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | Twinpig Biolab, Inc. (KR) | 2022-12-21 | — | — | EP | claimed |
| US-20220354957-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | US | claimed |
| US-11484601-B2 | Targeting M2-like tumor-associated macrophages by using melittin-based proapoptotic peptide | TWINPIGBIOLAB INC. (KR) | 2022-11-01 | — | — | US | claimed |
| US-20210324046-A1 | SYSTEMS AND METHODS FOR MANUFACTURE OF ENDOTOXIN-FREE HEMOGLOBIN-BASED DRUG SUBSTANCE | GOLD BLAZE, LTD. (SG) | 2021-10-21 | — | — | US | claimed |
| US-20210244823-A1 | TARGETING M2-LIKE TUMOR-ASSOCIATED MACROPHAGES BY USING MELITTIN-BASED PROAPOPTOTIC PEPTIDE | TWINPIGBIOLAB INC. (KR) | 2021-08-12 | — | — | US | claimed |
| US-20210236464-A1 | BENZOSELENOPHENE-BASED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND ANTIBODY-DRUG CONJUGATES INCLUDING THE SAME | AIMED BIO INC. (KR) | 2021-08-05 | — | — | US | claimed |
| WO-2021072194-A1 | STABILIZED HEMOGLOBIN COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS THEREOF | MEDICAL TECHNOLOGY ASSOCIATES II, INC. (US) | 2021-04-15 | — | — | WO | claimed |
| US-6080589-A | Neisseria meningitidis capsular polysacchride conjugates | CONNAUGHT LABORATORIES LIMITED (CA) | 2000-06-27 | — | — | US | claimed |
| US-6004770-A | MASS SPECTROMETRY SAMPLE PRESENTATION APPARATUSES DERIVATIZED WITH COMPLEXES INCLUDING AT LEAST ONE MOLECULE WHICH MODIFIES A BIOMOLECULE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 1999-12-21 | — | — | US | claimed |
| EP-0942996-A1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | Diatide, Inc. (US) | 1999-09-22 | — | — | EP | claimed |
| US-5951981-A | A CROSSLINKED THROMBOLYTIC PROTEINASE, E.G. FIBROLASE FROM AGKISTRODOON CONTORTRIX CONFORTRIX VENOM, AND A BINDING PEPTIDE THAT BINDS AT THE SITE OF BLOOD CLOTS AND THROMBI; SIDE EFFECTS REDUCTION | DIATIDE, INC. (US) | 1999-09-14 | — | — | US | claimed |
| US-5780606-A | Neisseria meningitidis capsular polysaccharide conjugates | CONNAUGHT LABORATORIES LIMITED (CA) | 1998-07-14 | — | — | US | claimed |
| WO-1998024917-A1 | THROMBOLYTIC AGENTS WITH ANTITHROMBOTIC ACTIVITY | DIATIDE, INC. (US) | 1998-06-11 | — | — | WO | claimed |
| EP-0747063-A2 | Neisseria meningitidis capsular polysaccharide conjugates | CONNAUGHT LABORATORIES LIMITED (CA) | 1996-12-11 | — | — | EP | claimed |
| EP-0369000-A4 | MACROCYCLIC COMPLEXES OF YTTRIUM, THE LANTHANIDES AND THE ACTINIDES HAVING PERIPHERAL COUPLING FUNCTIONALITIES | — | 1993-06-02 | — | — | EP | claimed |
| EP-0369000-A1 | MACROCYCLIC COMPLEXES OF YTTRIUM, THE LANTHANIDES AND THE ACTINIDES HAVING PERIPHERAL COUPLING FUNCTIONALITIES | Vallarino, Lidia M. (US) | 1990-05-23 | — | — | EP | claimed |
| WO-1989011868-A1 | MACROCYCLIC COMPLEXES OF YTTRIUM, THE LANTHANIDES AND THE ACTINIDES HAVING PERIPHERAL COUPLING FUNCTIONALITIES | COULTER ELECTRONICS, INC. (US) | 1989-12-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576896-B2 | Benzoselenophene-based compounds, pharmaceutical compositions and antibody-drug conjugates including the same | TPST2, SULT1E1, ABCB1 | KDM4E 213/4885MAPT 71/4885STAT3 3273/4885 |
| US-20210236464-A1 | BENZOSELENOPHENE-BASED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND ANTIBODY-DRUG CONJUGATES INCLUDING THE SAME | TPST2, SULT1E1, ABCB1 | KDM4E 213/4885MAPT 71/4885STAT3 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.